04:01 AM EDT, 03/31/2025 (MT Newswires) -- Eli Lilly ( LLY ) said Sunday its lepodisiran therapeutic candidate to reduce the production of heart disease risk factor lipoprotein(a) met its primary endpoint in a phase 2 study.

The trial showed the highest dose of the product helped lower the production of lipoprotein(a) in patients by an average of 93.9% over a 60 to 180-day period after treatment, the company said. Lepodisiran also met additional secondary endpoints of the trial.

The study showed no serious adverse events related to the treatment.